420 Magazine Background

Does Pot Make You Crazy-The Definitive Answer


New Member
Gone to Pot: The Association Between Cannabis and Psychosis
By Asif R. Malik, MD, and Deepak Cyril D'Souza, MD

April 2006, Vol. XXIII, No. 4

Cannabis or marijuana, has been consumed by humans for centuries and remains one of the most widely and commonly used illicit substances. Recently, there has been renewed interest in the association between cannabis use and psychosis. The purpose of this article is to review the evidence supporting and refuting the association between cannabis exposure and psychotic disorders, including schizophrenia.

As far back as 1845, Dr. Jacques- Joseph Moreau de Tours described psychotic phenomena with hashish use as:

[A]cute psychotic reactions, generally lasting but a few hours, but occasionally as long as a week; the reaction seemed doserelated and its main features included paranoid ideation, illusions, hallucinations, delusions, depersonalization, confusion, restlessness and excitement. There can be delirium, disorientation and marked clouding of consciousness.

In 1964, Gaoni and Mechoulam identified δ-9 tetrahydrocannabinol (δ-9-THC) as the principal psychoactive ingredient of cannabis.

The identification and cloning of a brain cannabinoid receptor (CB-1) in 1990 provided a jump start to renewed research on cannabinoids (Matsuda et al., 1990). Most of the psychoactive effects of cannabis are believed to be mediated by CB-1 receptors where δ-9-THC is a modest affinity (Ki=35 nmol to 80 nmol) low intrinsic activity partial agonist. A peripheral receptor later named CB-2 was identified in splenic tissue (Munro et al., 1993). Recent evidence suggests the presence of other brain cannabinoid receptors. The presence of cannabinoid receptors led to the logical search for endogenous cannabinoid receptor ligands, culminating in the discovery of anandamide and 2-arachidonoyl glycerol, two of the better known endogenous cannabinoids or endocannabinoids. Cannabinoid-1 receptors are distributed with high density in the cerebral cortex, particularly the frontal regions, basal ganglia, hippocampus, anterior cingulate cortex and cerebellum (Glass et al., 1997; Herkenham et al., 1990), brain regions that are relevant to their known effects. Further, these are also regions that have been implicated in the putative neural circuitry of psychosis. The primary effect of cannabinoids is the modulation of neurotransmitter release via activation of presynaptic CB1-Rs (reviewed in Demuth and Molleman, in press; Freund et al., 2003). Of note, some of these neurotransmitters (eg, dopamine and glutamate) have been implicated in the pathophysiology of psychosis.

The effects of herbal cannabis are a composite of a number of cannabinoid compounds, terpenoids and flavonoids. Thus, cannabidiol, a constituent of herbal cannabis, may offset some δ-9-THC effects (Zuardi et al., 1995). The ratio of the constituents of herbal cannabis varies, and this may result in important differences in its net effect.

Emerging data suggest an association between cannabis exposure and the development of schizophrenia (Table). Interest in the association between cannabis and schizophrenia received a major boost from the Swedish Conscript study, a large historical, longitudinal cohort study of all Swedes conscripted in 1969-1970 (Andreasson et al., 1987). Since Sweden mandates military service, 97% of males aged 18 to 20 years were included. Individuals who at age 18 reported having used cannabis >50 times were six times more likely than nonusers to have been diagnosed with schizophrenia in the ensuing 15 years. Adjusting for other relevant risk factors, including psychiatric diagnosis other than psychosis at conscription, reduced but did not eliminate the higher risk (odds ratio [OR]=2.3) of schizophrenia conferred by cannabis use.

A reanalysis and extension of the same Swedish conscript cohort reconfirmed that those who were heavy cannabis users by the age of 18 were 6.7 times more likely than nonusers to be hospitalized for schizophrenia 27 years later (Zammit et al., 2002). The OR for cannabis use and schizophrenia remained significant (1.2), albeit lower than in the original study, despite adjusting for a number of confounds, including low IQ and stimulant use. Further, the finding of an increased risk of schizophrenia conferred by cannabis use persisted after controlling for the possibility that cannabis use was a consequence of prodromal manifestations of psychosis.

Several recent prospective cohort studies complement studies using a historical approach. In a general population birth cohort study of 1,037 people born in Dunedin, New Zealand, and followed through age 26, individuals using cannabis at ages 15 and 18, compared to nonusers, had higher rates of both psychotic symptoms at age 26 (even after controlling for psychotic symptoms) and schizophreniform disorder predating the onset of cannabis use (Arseneault et al., 2002). Similarly, cohort studies from elsewhere have also reported a dose-response relationship in the increased risk of psychosis with cannabis exposure (Ferdinand et al., 2005a; Fergusson et al., 2003; Henquet et al., 2005; Stefanis et al., 2004; van Os et al., 2002; Weiser et al., 2002). Several studies of patients during their first-break psychosis suggested that cannabis use precedes or is coincident with the first psychotic break in patients with schizophrenia (Allebeck et al., 1993; Hambrecht and Hafner, 2000).

Are these data sufficient to constitute a causal relationship? And if so, how strong is the association? Temporality, strength, association, direction, dose-response or biological gradient, consistency, specificity, coherence, experimental evidence, and plausibility are some of the criteria that have been used to establish disease causality (Aiello and Larson, 2002).

Several studies reviewed here provided evidence of a dose-response relationship between cannabis exposure and the risk of psychosis. Most studies also provided evidence of direction by showing that the association between cannabis use and psychosis persists even after controlling for many potential confounding variables such as IQ, education, urbanicity, marital status and previous psychotic symptoms. With regard to temporality, several studies suggested that cannabis use precedes or coincides with the onset of psychosis. Further, there is also evidence that cannabis use may be associated with a lower age of schizophrenia onset (Green et al., 2004; Linszen et al., 1994). There is evidence for both the specificity of exposure (i.e., cannabis [Arseneault et al., 2002; Ferdinand et al., 2005a, 2005b; Zammit et al., 2002]) and specificity of the outcome (i.e., psychosis [Arseneault et al., 2002; Stefanis et al., 2004]). Experimental evidence from laboratory studies suggested that cannabinoids can induce transient short-lived psychosis in healthy individuals (D’Souza et al., 2004; Leweke et al., 2000). Further, relative to controls, patients with schizophrenia have been shown to be more vulnerable to the psychotomimetic effects of δ-9-THC (D’Souza et al., 2005). While it is out of the scope of this review, the interactions between cannabinoid receptor function and dopamine, glutamate and γ-aminobutyric acid receptor function provide potential mechanisms by which cannabis may “cause” psychosis (as reviewed in D’Souza et al., 2004, 2005).

One of the most obvious genetic risk factors for psychosis is a family history of psychosis. In a case-control study, cannabis users admitted for schizophrenia had a significantly greater familial risk of schizophrenia than patients with schizophrenia without cannabis use (McGuire et al., 1995). Consistent with these findings, data from the Edinburgh High Risk project showed that frequent cannabis use conferred a sixfold higher risk of schizophrenia in individuals with a family history of schizophrenia (Miller et al., 2001). Recently, a polymorphism of the catechol-O-methyltransferase gene has been reported to modulate the risk of schizophrenia conferred by cannabis (Caspi et al., 2005).

Emerging findings from postmortem (Dean et al., 2001; Zavitsanou et al., 2004), neurochemical (Leweke et al., 1999) and genetic (Ujike et al., 2002) studies suggested cannabinoid receptor system dysfunction contributes to the pathophysiology of schizophrenia. Thus, it is possible that cannabinoid receptor dysfunction is the substrate that links cannabis exposure and psychosis.

Finally, if cannabis causes psychosis in and of itself, then one would expect that any increase in the rates of cannabis use would be associated with increased rates of psychosis. However, in some areas where cannabis use has clearly increased (e.g., Australia), there has not been a commensurate increase in the rate of psychotic disorders (Degenhardt et al., 2003). Further, one might also expect that if the age of initiation of cannabis use decreases, there should also be a decrease in the age of onset of psychotic disorders. We are unaware of such evidence.

In conclusion, there is evidence for an association between cannabis and psychosis. It is clear that cannabinoids can cause acute transient psychotic symptoms or an acute psychosis. Also it is clear that cannabis can exacerbate psychosis in individuals with an established psychotic disorder. However, whether cannabis causes a persistent de novo psychosis independent of any other risk factors is not supported by the existing literature. More likely, cannabis is a component cause that interacts with other factors (e.g., genetic risk) to induce psychosis.

Nevertheless, in the absence of known causes of schizophrenia, the role of component causes such as cannabis use remains important and warrants further study. Finally, studying the role of exogenous cannabinoids in the development of psychosis will need to be complemented by further studying a possible role of endocannabinoid dysfunction in the pathophysiology of psychosis.

Dr Malik is a fourth year resident in psychiatry and Dr D'Souza is associate professor of psychiatry, both at Yale University School of Medicine, New Haven, Conn.

Aiello AE, Larson EL (2002), Causal inference: the case of hygiene and health. Am J Infect Control 30(8):503-511.

Allebeck P, Adamsson C, Engstrom A, Rydberg U (1993), Cannabis and schizophrenia: a longitudinal study of cases treated in Stockholm County. [Published erratum Acta Psychiatr Scand 88(4):304.] Acta Psychiatr Scand 88(1):21-24.

Andreasson S, Allebeck P, Engstrom A, Rydberg U (1987), Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 2(8574): 1483-1486.

Arseneault L, Cannon M, Poulton R et al. (2002), Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 325(7374):1212-1213 [see comment].

Caspi A, Moffitt TE, Cannon M et al. (2005), Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 57(10):1117-1127.

Dean B, Sundram S, Bradbury R et al. (2001), Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103(1):9-15.

Degenhardt L, Hall W, Lynskey M (2003), Testing hypotheses about the relationship between cannabis use and psychosis. Drug Alcohol Depend 71(1):37-48.

Demuth DG, Molleman A (in press), Cannabinoid signalling. Life Sciences.

D’Souza DC, Abi-Saab WM, Madonick S et al. (2005), Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 57(6):594-608.

D’Souza DC, Perry E, MacDougall L et al. (2004), The psychotomimetic effects of intravenous delta- 9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29(8):1558-1572.

Ferdinand RF, Sondeijker F, van der Ende J et al. (2005a), Cannabis use predicts future psychotic symptoms, and vice versa. Addiction 100(5):612-618 [see comment].

Ferdinand RF, van der Ende J, Bongers I et al. (2005b), Cannabis-psychosis pathway independent of other types of psychopathology. Schizophr Res 79(2-3):289-295.

Fergusson DM, Horwood LJ, Swain-Campbell NR (2003), Cannabis dependence and psychotic symptoms in young people. Psychol Med 33(1):15-21 [see comment].

Freund TF, Katona I, Piomelli D (2003), Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83(3):1017-1066.

Glass M, Dragunow M, Faull RL (1997), Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77(2):299-318.

Green AI, Tohen MF, Hamer RM et al. (2004), First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res 66(2-3):125- 135 [see comment].

Hambrecht M, Hafner H (2000), Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Aust N Z J Psychiatry 34(3): 468-475.

Henquet C, Krabbendam L, Spauwen J et al. (2005), Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 330(7481):11 [see comment].

Herkenham M, Lynn AB, Little MD et al. (1990), Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87(5):1932-1936.

Leweke FM, Giuffrida A, Wurster U et al. (1999), Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10(8):1665-1669.

Leweke FM, Schneider U, Radwan M et al. (2000), Different effects of nabilone and cannabidiol on binocular depth inversion in Man. Pharmacol Biochem Behav 66(1):175-181.

Linszen DH, Dingemans PM, Lenior ME (1994), Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 51(4):273-279.

Matsuda LA, Lolait SJ, Brownstein MJ et al. (1990), Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346(6284): 561-564 [see comment].

McGuire PK, Jones P, Harvey I et al. (1995), Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophr Res 15(3): 277-281.

Miller P, Lawrie SM, Hodges A et al. (2001), Genetic liability, illicit drug use, life stress and psychotic symptoms: preliminary findings from the Edinburgh study of people at high risk for schizophrenia. Soc Psychiatry Psychiatr Epidemiol 36(7):338-342.

Munro S, Thomas KL, Abu-Shaar M (1993), Molecular characterization of a peripheral receptor for cannabinoids. Nature 365(6441):61-65 [see comment].

Stefanis NC, Delespaul P, Henquet C et al. (2004), Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction 99(10): 1333-1341 [see comment].

Ujike H, Takaki M, Nakata K et al. (2002), CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry 7(5):515-518.

van Os J, Bak M, Hanssen M et al. (2002), Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 156(4):319-327.

Weiser M, Knobler HY, Noy S, Kaplan Z (2002), Clinical characteristics of adolescents later hospitalized for schizophrenia. Am J Med Genet 114(8):949-955.

Zammit S, Allebeck P, Andreasson S et al. (2002), Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 325(7374):1199 [see comment].

Zavitsanou K, Garrick T, Huang XF (2004), Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28(2):355-360.

Zuardi AW, Morais SL, Guimaraes FS, Mechoulam R (1995), Antipsychotic effect of cannabidiol. J Clin Psychiatry 56(10):485-486 [letter].


New Member
Re: Does Pot Make You Crazy--THE DEFINITIVE ANSWER

For those of you who would rather dispense with all the reading cause like me, you're lazy fucks.. just scroll down to the bold print. :peace: :3:


New Member
Re: Does Pot Make You Crazy--THE DEFINITIVE ANSWER

Pinch said:
For those of you who would rather dispense with all the reading cause like me, you're lazy fucks.. just scroll down to the bold print. :peace: :3:

hahaha you nailed it on the head, after doing econ homework any big words = BAD hahaha :laugh2:


New Member
Re: Does Pot Make You Crazy--THE DEFINITIVE ANSWER

For those of you who would rather dispense with all the reading cause like me, you're lazy fucks.. just scroll down to the bold print. :peace: :3:

not so much being lazy as it is a SCHEDULING ISSUE! lol
damn, that's a lot of typing but kudos to you pinch for the info.


New Member
Schizophrenia is a genetic condition and is not caused by Marijuana. However, people with conditions such as Schizophrenia or psychosis may see a worsing in their condition as a result of smoking pot. I have depression (Boarderline Personality Disorder), and I actually treat the depression with Marijuana. But when I can't get Pot, like this last week because no one has any, it made my depression even worse. I would like to grow, but right now, I have no place to grow it. Anyhow, I cannot logically deduct how Pot could be the cause of a severe mental condition such as Schizophrenia or pyschosis.


New Member
I know when i use a bit of weed, like smoke everyday for a week for example and then stop due to goals i set myself in sport ect.. i end up very aggitated and agressive for about a week. I wouldnt say that these withdrawals are skitz or any thing but hey.... im not a doc and to suddenly stop smoking makes me skitz.... or does it.... yep id say skitz is a good way to describe how i feel when i wanna snap necks coz i havent had a smoke. Definently a down side to smoking pot.... peace.


New Member
I've smoked everyday for the past 3 years and all its done to me has dropped my IQ 3 points, oddly, and made me a real relaxed person. But I haven't had a smoke in 4 days and yes I'm quite angry, I keep getting the urge to punch something every time some thing that irritates me happens, such as not having any weed :(



Member of the Month: May 2009, Oct 2010, Sept 2017
Define "crazy." If your definition doesn't match mine, then this whole concept is irrelevant.

Schizophrenia... While it is said that some are genetically predisposed to it, most agree that there is still a "triggering event." The only problem being that if you look at the lengthy list of speculated triggers - and yes, some are quite grisly and one should never have to suffer them - you'll find that just about everyone on the planet has experienced some number of them.

Some have wondered if schizophrenia is just a fancy term for "the psyche couldn't take (the event) and the result is that it tries to create a reality in which it survives - and then must exist in both."

IDK. Have known a few so affected, from casual acquaintances to one little soul-shaker that I probably know better than anyone. Most of them have some sort of traumatic experiences in their background.

Some of them used MJ before being diagnosed. Some did not. One tried and had some extremely bad reactions.

If MJ can be considered a causal factor as pertains to schizophrenia, I guess they'll just have to put it at the bottom of a very large list.

As for the lack of MJ making people loopy... Some people use MJ to such an extent that they form a dependance (No, I really don't care what the experts say on this one lol.), just like some people do with alcohol. In both cases, when you remove the crutch, the person tends to stumble and fall (sometimes in a figurative sense).

Know a couple of people who have more-or-less stopped taking ALL of their meds and (for the most part) they seem to be making it through life. But then again there's another who has done the same thing, and when she told me that she had gone off her meds, my only thought was, "And you thought I didn't already KNOW this?"

So as far as MJ and schizophrenia, I'm thinking that it's like everything else: Your Mileage May Vary.


New Member
well, i didn't read that whole thing because it was to long, i'll just say that when i was smoking marijuana all day everyday (for 2 years) in my homecountry i became extremely paranoid and started thinking that the american government (i'm from new zealand, go figure) was watching my every move.

i'd never up until then experienced any sort of psychosis, depression or any mental disorder.

all symptoms were completely gone after i stopped smoking for a few months and i've never experienced anything like that since.

i did smoke for a long time after my head-clearing months and never had any other problems, don't smoke now, i moved to georgia/USA and am to afraid of being put in jail to look for contacts.

just my two cents.
Top Bottom